While developing a new pharmaceutical product is one of the most interesting and rewarding activities to partake in, it is also extremely challenging. It is a given that drug development projects will not always succeed and the more innovative they are, the higher the likelihood of failure. There is no way to eliminate the risk of failure. However, there are ways to reduce these risks.
Traditionally, large companies have dominated the drug discovery and development space, however there are now many smaller pharma and biotech companies experiencing huge success in early discovery. Quite a substantial number of these progress their projects to at least clinical proof of concept prior to out-licensing the product to big pharma. In many cases, when the product is for orphan treatment or niche products, small companies have successfully developed their products all the way to the market. As smaller start-ups and biotech companies enter the development space, creativity and innovation are subsequently increasing. Often, drug development and drug discovery are coupled together and viewed as the same, when in fact, they are completely different.
While drug discovery involves progressing an idea to a drug candidate, drug development focuses on progressing the drug candidate to become a new pharmaceutical product on the commercial market . When thinking about a medicine, most people involved in drug discovery focus on the drug substance also known as the active pharmaceutical ingredient/drug substance (API/DS), a small or large molecule that has a certain effect
Oxybreathe is right in the critical phase between drug discovery and drug substance. Since we are repurposing drug substances and creating a new Bioactive molecule, dosage is calculated and packaging can commence for clinical trials.
When manufacturing in large quantities, the development process needs to have manufacturing and control methods that are suitable for large-scale equipment, are reproducible and give an acceptable cost of goods. Moreover, safety, efficacy and quality must be carefully documented so that the relevant information can be approved by authorities in different countries. In fact, most of the development work is performed in order to produce the right documentation. As part of the approval process, you must also be able to prove that you have done all the right things. Pharmaceutical development can also be viewed as the process of documenting safety, efficacy and manufacturability in safety studies, clinical studies and tech transfer. The dosage form and package should not be considered as less important. They typically affect pharmacokinetics, variability, side effects, stability, convenience and cost, meaning they will have a profound impact on therapeutic effect, safety and the profitability of a drug product.
Once a drug passes these stages, it enters clinical development, which involves carefully designed trials in humans to test safety, effectiveness, and potential side effects. Clinical trials occur in phases. Phase I trials are the first step in human testing and focus primarily on safety, usually involving a small group of healthy volunteers or patients. If results are positive, the drug progresses to Phase II, where a larger group of patients is studied to determine whether the drug works as intended and to continue monitoring safety. Phase III involves thousands of patients across multiple sites and is designed to confirm effectiveness, compare the drug against existing treatments, and detect any adverse effects on a larger scale. If successful, the results are submitted to regulatory authorities for approval.
India's pharmaceutical industry, often dubbed the "pharmacy of the world," plays a crucial role both domestically and globally. As of 2023, India ranks third globally in pharmaceutical production by volume and 14th by value. The sector is composed of over 3,000 drug companies and approximately 10,500 manufacturing units, providing affordable and high-quality medicines across more than 200 countries. Notably, Indian firms supply over 50% of the global demand for vaccines, 40% of generic demand in the US, and 25% of all medicine dispensed in the UK.
Domestically, the Indian pharma market was valued at approximately USD 50 billion in 2023, with expectations to grow to USD 130 billion by 2030, driven by factors such as rising health awareness, expanding health insurance coverage, and increasing demand for chronic care drugs. India’s stronghold in Active Pharmaceutical Ingredients (APIs) has also been a key strength.
India's cost efficiency, skilled workforce, and a robust network of manufacturing units have also enabled it to produce complex generics, Active Pharmaceutical Ingredients (APIs), and increasingly, biosimilars and specialty drugs. Its strength in reverse engineering and formulation development allows Indian companies to produce medicines at significantly lower costs compared to their Western counterparts, without compromising quality. These competitive advantages have positioned India as a key partner in achieving global health goals, particularly in low- and middle-income countries, where access to affordable medicines remains a critical issue.
In the United States, costs were higher after adjusting for earnings drug developers could have made if they had invested these amounts in other activities and for drugs that never made it to the market. With these adjustments, researchers estimated a median research and development cost of $708 million across the 38 drugs examined, with the average cost rising to $1.3 billion driven by a small number of high-cost outliers. It is my personal belief that the cost is so high to drive entrepreneurs out of the picture, not to mention the amount of money just evaporating into thin air during the whole process with little or no end in sight usually.
The projected revenue for the BRICS Pharmaceuticals market in 2025 is expected to reach a staggering $296.97B. Looking ahead, the revenue is anticipated to exhibit an annual growth rate of 5.46%, leading to a market volume of $387.32B by 2030. In Brazil, the pharmaceutical market is experiencing a rise in demand for generic drugs due to their affordability and accessibility. The cost of drug development is being driven down globally and the desire to keep costs in check is proof of global awareness to defer costs.
In fact, such has been the rate of progress that their collective tag as ‘emerging’ nations is undoubtedly out of date. The chrysalis has fallen away and their metamorphosis into markets of global importance is now drawing widespread corporate attention. IMS Health data shows that in 2011 China cemented its place as the third largest pharmaceutical market in the world – almost 50 per cent bigger than Germany in fourth place – while Brazil overtook the UK, Italy, Spain and Canada to take sixth spot. Russia and India enjoyed similarly impressive uplifts.
Oxybreathe is a disruptive, low-cost alternative to the overpriced respiratory medications that dominate today’s global market. This breakthrough formula represents a rare opportunity to meet a massive unmet medical need while unlocking extraordinary commercial potential. At a time when U.S. drug development costs often reach billions of dollars, Oxybreathe offers a leaner, faster path to market. By launching first in high-demand regions, we can bypass traditional bottlenecks, generate early revenue, and scale production to drive costs even lower—delivering both accessibility for patients and profitability for investors.
The COVID-19 pandemic exposed critical weaknesses in global healthcare: inequitable access, political interference in science, and delays in distributing life-saving treatments. Governments and international agencies now face mounting pressure to avoid repeating these mistakes and to strengthen their preparedness for the next crisis. Oxybreathe positions itself as a vital partner in that effort—affordable, effective, and deployable at scale where it is needed most.
For investors, this is more than a pharmaceutical opportunity—it is entry into a multi-billion-dollar respiratory market with extraordinary growth potential. By leveraging accelerated approval pathways in BRICS nations and expanding laterally across emerging markets, Oxybreathe is positioned to gain early traction, expand rapidly, and become the go-to solution for respiratory care worldwide.
Our strategy is built on speed and impact. While the U.S. pathway requires years and billions, Oxybreathe can reach international markets—beginning with BRICS nations representing 40% of the world’s population—in less than two years. These countries bear the greatest burden of respiratory disease, ensuring strong demand, rapid adoption, and robust early revenues.
Beyond the financial upside, Oxybreathe offers strategic importance on a global scale. It is not just another drug—it is a tool for governments to strengthen pandemic preparedness, reduce healthcare costs, and expand access to treatment. For investors, it represents a rare opportunity: a scalable, high-impact solution with the power to transform both global health and market dynamics.
The gatekeepers are gone. In 2025, the traditional network pitchroom has been replaced by inboxes and digital dashboards. What matters now isn’t who you know—it’s how refined, resonant, and ready our pitch is. We will be video journaling every step of the way for a unique perspective on how to bring a drug to market. Netflix is a major player, but their standards have sharpened. There are a few ways to go about this, but here are the most common ways to get noticed by Netflix.
Through a production company: Partner with small to mid-tier producers who have first-look deals
Via a manager/agent: Even newer managers can get meetings if the deck is polished
Staff writer/contest wins: Leverage industry-recognized screenwriting labs
Co-production with indie studio: Use AI visualizations to show you're production-ready
We will explore all available resources as the filming progresses.
Over the next five years, Oxybreathe is expected to transition from clinical development to becoming a leading low-cost respiratory therapy with global reach. In the first two years, the focus will remain on completing Phase II trials and advancing into Phase III, while expanding research collaborations and initiating early access programs in underserved regions. By the third year, regulatory submissions are anticipated in the United States, Europe, and key emerging markets, supported by strategic licensing and manufacturing scale-up agreements. In the fourth year, Oxybreathe is projected to achieve initial market entry, targeting populations with limited access to affordable respiratory care and hospitals seeking cost-effective alternatives. At this stage, revenues could surpass $500 million, driven by rapid adoption in cost-sensitive markets. By the fifth year, Oxybreathe is expected to secure approvals across all major markets, reaching annual revenues exceeding $2 billion and establishing itself as the global leader in accessible respiratory therapies. Beyond commercial success, Oxybreathe will deliver significant social impact by reducing hospitalization rates and improving the quality of life for millions of patients worldwide, while providing investors with strong returns through sustainable growth and market leadership.